BioRestorative Therapies (BRTX) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Virax Biolabs Group is the larger company by market cap ($2.7 million vs $2.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRTX | VRAX |
|---|---|---|
| Share price | $1.89 | $1.99 |
| Market cap | $2.61M | $2.68M |
| 1-day change | -15.63% | -5.69% |
| EPS (TTM) | $-21.40 | $-11.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.40 | $21.75 |
| 52-week low | $1.75 | $1.83 |
| Distance from 52-week high | -94.51% | -90.85% |
| Analyst consensus | buy | — |
| Avg. price target upside | +15773.02% | — |
| Average volume | 26.05K | 650.11K |
| Shares outstanding | 1.38M | 1.34M |
| Employees | 13 | 26 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BioRestorative Therapies
BRTX stock →BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
Healthcare · Biotechnology · 13 employees
About Virax Biolabs Group
VRAX stock →Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Healthcare · Biotechnology · 26 employees
BRTX vs VRAX FAQ
Which is bigger, BioRestorative Therapies or Virax Biolabs Group?
Virax Biolabs Group (VRAX) is larger, with a market capitalization of $2.68M compared with $2.61M for BioRestorative Therapies (BRTX).
Are BioRestorative Therapies and Virax Biolabs Group in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.